Abstract
PurposeTo evaluate refractive changes after anti‐vascular endothelial growth factor (anti‐VEGF) injections for the treatment of diabetic macular edema (DME).MethodsParticipants in this retrospective study were 37 patients (37 eyes) with DME, who received intravitreal anti‐VEGF injections with either ranibizumab or aflibercept. Spherical equivalent refractive power was evaluated before treatment and at least one month after the last injection where no fluid existed. Demographic characteristics, visual acuity, central retinal thickness and the number of injections were recorded and analyzed.ResultsChanges in visual acuity and central retinal thickness were statistically significant before and after injections. The spherical equivalent refractive power did not differ significantly pre‐ and post‐ injections.ConclusionsIntravitreal anti‐VEGF injections did not seem to affect the refractive power of patients with DME. Therefore, appropriate spectacle correction can be prescribed any time during ongoing treatment with anti‐VEGF agents.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
